title: Effect of pravastatin in the treatment of hypercholesterolemia after renal transplantation under cyclosporine and prednisone.
authors.affiliation: Nephrology Department, Hospital de Bellvitge, Barcelona, Spain.
authors.forename: A M
authors.initials: AM
authors.lastname: Castelao
authors.forename: J M
authors.initials: JM
authors.lastname: Grinyó
authors.forename: M J
authors.initials: MJ
authors.lastname: Castiñeiras
authors.forename: C
authors.initials: C
authors.lastname: Fiol
authors.forename: S
authors.initials: S
authors.lastname: Gilvernet
authors.forename: D
authors.initials: D
authors.lastname: Seron
authors.forename: J
authors.initials: J
authors.lastname: Torras
authors.forename: J M
authors.initials: JM
authors.lastname: Cruzado
authors.forename: J
authors.initials: J
authors.lastname: Alsina
mesh_terms: D000328:Adult; D016632:Apolipoprotein A-I / Q000097:blood; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D016572:Cyclosporine / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D007165:Immunosuppression Therapy / Q000379:methods; D016030:Kidney Transplantation / Q000009:adverse effects / Q000276:immunology / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D017035:Pravastatin / Q000627:therapeutic use*; D011241:Prednisone / Q000627:therapeutic use*
chemical_list: D016632:Apolipoprotein A-I; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D016853:Muromonab-CD3; D016572:Cyclosporine; D002784:Cholesterol; D017035:Pravastatin; D011241:Prednisone